<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02914275</url>
  </required_header>
  <id_info>
    <org_study_id>CSLCT-QIV-15-03</org_study_id>
    <nct_id>NCT02914275</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.</brief_title>
  <official_title>A Phase 3, Randomized, Multicenter, Observer-blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) With a US-licensed Quadrivalent Inactivated Comparator Influenza Virus Vaccine (Comparator QIV) in a Pediatric Population 6 Months Through 59 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seqirus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seqirus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to assess the immune (antibody) response and safety of a Seqirus split
      virion, inactivated Quadrivalent Influenza Vaccine (Seqirus QIV), in comparison with a US
      licensed 2016/2017 Quadrivalent Influenza Vaccine (comparator QIV) in a healthy pediatric
      population 6 months through 59 months of age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 27, 2016</start_date>
  <completion_date type="Actual">August 11, 2017</completion_date>
  <primary_completion_date type="Actual">March 9, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Geometric Mean Titer (GMT) Ratio of Each Virus Strain.</measure>
    <time_frame>Postvaccination (28 days after last vaccination)</time_frame>
    <description>Noninferiority of Seqirus QIV compared to comparator QIV was assessed by hemagglutination inhibition (HI) antibody geometric mean titer (GMT) for each viral strain included in the vaccines. The GMT ratio is defined as the geometric mean of the postvaccination HI titer for the US-licensed comparator QIV over the geometric mean of the postvaccination HI titer for Seqirus QIV.
B/VIC = B/Victoria B/YAM = B/Yamagata</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Difference in Seroconversion Rate (SCR) for Each Virus Strain.</measure>
    <time_frame>Postvaccination (28 days after last vaccination)</time_frame>
    <description>Noninferiority of Seqirus QIV compared to comparator QIV will be assessed by seroconversion rate (SCR) for each viral strain. SCR is defined as the percentage of subjects with either a prevaccination HI titer &lt; 1:10 and a postvaccination HI titer ≥ 1:40, or a prevaccination HI titer ≥ 1:10 and a ≥ 4-fold increase in postvaccination HI titer. For the SCR comparison, the difference between the SCR for each vaccine (for each strain) will be determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Solicited Local Adverse Reactions and Solicited Systemic Adverse Events (AE)</measure>
    <time_frame>Postvaccination (up to 7 days after vaccination)</time_frame>
    <description>Frequency and severity of solicited local adverse reactions and systemic AEs for 7 days after each vaccination dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cellulitis-like Reactions</measure>
    <time_frame>Postvaccination (up to 28 days after each vaccination)</time_frame>
    <description>Frequency of cellulitis-like reactions for at least 28 days after each vaccination dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Unsolicited AEs</measure>
    <time_frame>Postvaccination (up to 28 days after vaccination)</time_frame>
    <description>Frequency and severity of unsolicited AEs for at least 28 days after each vaccination dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAE)</measure>
    <time_frame>180 days after the last vaccination dose.</time_frame>
    <description>Frequency of SAEs for 180 days after the last vaccination dose. SAE = serious adverse events, AESI = adverse event of special interest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean of Hemagglutination Titers (HI GMTs) Prevaccination (Day 1) and Postvaccination (Study Exit Visit) of Each Virus Strain</measure>
    <time_frame>28 days after last vaccination.</time_frame>
    <description>The humoral immune response will be assessed for Seqirus QIV &amp; comparator QIV. Serum HI titers against the 4 influenza vaccine strains will be used to calculate geometric mean of HI titers prevaccination &amp; postvaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Rates (SCRs) of Each Virus Strain</measure>
    <time_frame>28 days after last vaccination</time_frame>
    <description>The humoral immune response will be assessed for Seqirus QIV &amp; comparator QIV. Serum HI titers against the 4 influenza vaccine strains will be used to calculate SCRs defined as the % of subjects with either a prevaccination HI titer &lt; 1:10 and a postvaccination HI titer ≥ 1:40 or a prevaccination titer ≥ 1:10 and a ≥ 4-fold increase in postvaccination titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection Rates of Each Virus Strain</measure>
    <time_frame>28 days after last vaccination.</time_frame>
    <description>The humoral immune response will be assessed for Seqirus QIV &amp; comparator QIV. Serum HI titers against the 4 influenza vaccine strains will be used to calculate the percentage of subjects with a titer ≥40 (seroprotection rates) at Day 1 and at Study Exit Visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Increase (GMFI) of Each Virus Strain</measure>
    <time_frame>Prevaccination (Day 1) and Postvaccination (28 days after last vaccination)</time_frame>
    <description>The humoral immune response will be assessed for Seqirus QIV &amp; comparator QIV. Serum HI titers against the 4 influenza vaccine strains will be used to calculate GMFIs, defined as the geometric mean fold titer change (rise) from Day 1 to Study Exit Visit.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2250</enrollment>
  <condition>Influenza, Human</condition>
  <arm_group>
    <arm_group_label>Seqirus QIV Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Seqirus Quadrivalent Inactivated Influenza Vaccine - Subjects 6 months through 35 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seqirus QIV Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Seqirus Quadrivalent Inactivated Influenza Vaccine - Subjects 36 months through 59 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator QIV Cohort A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparator Quadrivalent Inactivated Influenza Vaccine - Subjects 6 months through 35 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator QIV Cohort B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparator Quadrivalent Inactivated Influenza Vaccine - Subjects 36 months through 59 months of age</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Seqirus Quadrivalent Inactivated Influenza Vaccine</intervention_name>
    <description>The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2016/2017 influenza season). Subjects will receive one or two doses according to the recommendations of the Advisory Committee on Immunization Practices for the United States 2016-17 Influenza Season. Preferred sites for intramuscular injection are the anterolateral aspect of the thigh in infants 6 months through 11 months of age, the anterolateral aspect of the thigh (or the deltoid muscle of the arm if muscle mass is adequate) in children 12 months through 35 months of age.</description>
    <arm_group_label>Seqirus QIV Cohort A</arm_group_label>
    <arm_group_label>Seqirus QIV Cohort B</arm_group_label>
    <other_name>Seqirus QIV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator Quadrivalent Inactivated Influenza Vaccine</intervention_name>
    <description>The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2016/2017 influenza season. Subjects will receive one or two doses according to the recommendations of the Advisory Committee on Immunization Practices for the United States 2016-17 Influenza Season. Preferred sites for intramuscular injection of the non-dominant arm in children 36 months through 59 months of age.</description>
    <arm_group_label>Comparator QIV Cohort A</arm_group_label>
    <arm_group_label>Comparator QIV Cohort B</arm_group_label>
    <other_name>Comparator QIV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subject 6 months through to 59 months of age at the time of first
             vaccination and born between 36 and 42 weeks of gestation;

          -  Parent or legally acceptable representative able to provide written informed consent
             and be willing and able to adhere to all protocol requirements including blood draws.

          -  Subject is in generally good health as per the Investigator's medical judgment

        Exclusion Criteria:

          -  History of allergic reactions to egg proteins or any components of the Study Vaccines;

          -  History of serious adverse reactions to any influenza vaccines;

          -  History of Guillain-Barré syndrome or other demyelinating disease such as
             encephalomyelitis and transverse myelitis;

          -  History of licensed or investigational influenza vaccination in the last 6 months;

          -  Clinical signs of active infection and/or an axillary temperature of ≥ 99.5°F / (≥
             37.5 °C) on the day of vaccination or within 48 hours preceding vaccination.

          -  Current or recent, acute or chronic medical conditions that in the opinion of the
             Investigator are clinically significant and/or unstable

          -  History of any seizures, with the exception of a single febrile seizure;

          -  Self-reported or known seropositivity suggestive of acute or chronic viral infection
             for human immunodeficiency virus, hepatitis B or hepatitis C;

          -  Known or suspected congenital or acquired immunosuppressive conditions;

          -  Current or recent immunosuppressive or immunomodulatory therapy

          -  Current or medical history of malignant neoplasms;

          -  Administration of immunoglobulin and/or any blood products within the previous 90 days
             preceding the administration of the Study Vaccine or planned administration during the
             study;

          -  Participation in a clinical trial or use of an investigational compound within 28 days
             prior to or 28 days after receiving the Study Vaccine, or plans to enter a study
             during this period;

          -  Vaccination with a licensed vaccine 21 days (for live or inactivated vaccines) prior
             to receiving the Study Vaccine, or plans to receive any licensed vaccine prior to the
             Study Exit Visit.

          -  Medical conditions or treatment contraindicating intramuscular vaccination due to
             increased risk of bleeding.

          -  Family members of the employees of the Investigator or study center with direct
             involvement in the study, or with other clinical studies under the direction of that
             Investigator or study center.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>59 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site 434</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 442</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 430</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 437</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 423</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 397</name>
      <address>
        <city>Ontario</city>
        <state>California</state>
        <zip>91762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 445</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 402</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 425</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 418</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 426</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 289</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 390</name>
      <address>
        <city>Augusta</city>
        <state>Kansas</state>
        <zip>67010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 421</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 422</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 443</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 420</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 441</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 393</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 436</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 285</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 429</name>
      <address>
        <city>Asheboro</city>
        <state>North Carolina</state>
        <zip>27203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 446</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 427</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45419</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 419</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 439</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 308</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 444</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 283</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 282</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 288</name>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 395</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 431</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 424</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 428</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 440</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 433</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 435</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 438</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>September 22, 2016</study_first_submitted>
  <study_first_submitted_qc>September 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2016</study_first_posted>
  <results_first_submitted>September 17, 2018</results_first_submitted>
  <results_first_submitted_qc>December 30, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 23, 2019</results_first_posted>
  <disposition_first_submitted>February 22, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>February 22, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 26, 2018</disposition_first_posted>
  <last_update_submitted>December 30, 2018</last_update_submitted>
  <last_update_submitted_qc>December 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 24, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT02914275/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 22, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT02914275/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled from 27 September 2016 to 11 August 2017 from 39 study sites in the United States of America.</recruitment_details>
      <pre_assignment_details>A total of 2339 subjects were screened. A total of 2250 subjects were randomized to study treatment. Due to not having valid informed consent, 3 subjects were removed from the clinical database. Therefore, overall 2247 subjects gave informed consent and were included in the analysis set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Seqirus QIV</title>
          <description>Subjects 6 months through 59 months of age who received Seqirus Quadrivalent Inactivated Influenza Vaccine.</description>
        </group>
        <group group_id="P2">
          <title>Comparator QIV</title>
          <description>Subjects 6 months through 59 months of age who received Comparator Quadrivalent Inactivated Influenza Vaccine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1687"/>
                <participants group_id="P2" count="563"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Included in Clinical Database / FAS</title>
              <participants_list>
                <participants group_id="P1" count="1684"/>
                <participants group_id="P2" count="563"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1566"/>
                <participants group_id="P2" count="521"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Excluded due to invalid informed consent</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Full Analysis Set was used for analysis of subject characteristics and comprised all subjects whose parent(s)/guardian(s) had given informed consent and who were randomized to treatment. Screening failures were not included in the FAS.</population>
      <group_list>
        <group group_id="B1">
          <title>Seqirus QIV</title>
          <description>Subjects 6 months through 59 months of age who received Seqirus Quadrivalent Inactivated Influenza Vaccine.</description>
        </group>
        <group group_id="B2">
          <title>Comparator QIV</title>
          <description>Subjects 6 months through 59 months of age who received Comparator Quadrivalent Inactivated Influenza Vaccine.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1684"/>
            <count group_id="B2" value="563"/>
            <count group_id="B3" value="2247"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.6" spread="14.70"/>
                    <measurement group_id="B2" value="36.5" spread="14.68"/>
                    <measurement group_id="B3" value="36.6" spread="14.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>6 through 35 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="700"/>
                    <measurement group_id="B2" value="235"/>
                    <measurement group_id="B3" value="935"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 through 59 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="984"/>
                    <measurement group_id="B2" value="328"/>
                    <measurement group_id="B3" value="1312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="820"/>
                    <measurement group_id="B2" value="268"/>
                    <measurement group_id="B3" value="1088"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="864"/>
                    <measurement group_id="B2" value="295"/>
                    <measurement group_id="B3" value="1159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="434"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="594"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1243"/>
                    <measurement group_id="B2" value="400"/>
                    <measurement group_id="B3" value="1643"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="361"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="484"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1205"/>
                    <measurement group_id="B2" value="391"/>
                    <measurement group_id="B3" value="1596"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1684"/>
                    <measurement group_id="B2" value="563"/>
                    <measurement group_id="B3" value="2247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.36" spread="4.224"/>
                    <measurement group_id="B2" value="15.40" spread="4.149"/>
                    <measurement group_id="B3" value="15.37" spread="4.205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prevaccination Axillary Temperature</title>
          <units>°F</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97.17" spread="0.963"/>
                    <measurement group_id="B2" value="97.25" spread="0.935"/>
                    <measurement group_id="B3" value="97.19" spread="0.936"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vaccination against influenza 2015/2016 season</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="845"/>
                    <measurement group_id="B2" value="294"/>
                    <measurement group_id="B3" value="1139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Geometric Mean Titer (GMT) Ratio of Each Virus Strain.</title>
        <description>Noninferiority of Seqirus QIV compared to comparator QIV was assessed by hemagglutination inhibition (HI) antibody geometric mean titer (GMT) for each viral strain included in the vaccines. The GMT ratio is defined as the geometric mean of the postvaccination HI titer for the US-licensed comparator QIV over the geometric mean of the postvaccination HI titer for Seqirus QIV.
B/VIC = B/Victoria B/YAM = B/Yamagata</description>
        <time_frame>Postvaccination (28 days after last vaccination)</time_frame>
        <population>The Per-Protocol Population (PPS) comprised all subjects in the Evaluable Population who did not have any protocol deviations that were medically assessed as potentially impacting on immunogenicity results.</population>
        <group_list>
          <group group_id="O1">
            <title>Seqirus QIV</title>
            <description>Subjects 6 months through 59 months of age who received Seqirus Quadrivalent Inactivated Influenza Vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Comparator QIV</title>
            <description>Subjects 6 months through 59 months of age who received Comparator Quadrivalent Inactivated Influenza Vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>The Geometric Mean Titer (GMT) Ratio of Each Virus Strain.</title>
          <description>Noninferiority of Seqirus QIV compared to comparator QIV was assessed by hemagglutination inhibition (HI) antibody geometric mean titer (GMT) for each viral strain included in the vaccines. The GMT ratio is defined as the geometric mean of the postvaccination HI titer for the US-licensed comparator QIV over the geometric mean of the postvaccination HI titer for Seqirus QIV.
B/VIC = B/Victoria B/YAM = B/Yamagata</description>
          <population>The Per-Protocol Population (PPS) comprised all subjects in the Evaluable Population who did not have any protocol deviations that were medically assessed as potentially impacting on immunogenicity results.</population>
          <units>Geometric Mean Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1456"/>
                <count group_id="O2" value="484"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1456"/>
                    <count group_id="O2" value="484"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="370.0" lower_limit="345.13" upper_limit="396.55"/>
                    <measurement group_id="O2" value="311.7" lower_limit="276.88" upper_limit="350.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1455"/>
                    <count group_id="O2" value="484"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="436.8" lower_limit="403.04" upper_limit="473.28"/>
                    <measurement group_id="O2" value="589.1" lower_limit="516.42" upper_limit="671.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/YAM</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1456"/>
                    <count group_id="O2" value="484"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5" lower_limit="23.93" upper_limit="27.06"/>
                    <measurement group_id="O2" value="29.7" lower_limit="26.51" upper_limit="33.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/VIC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1456"/>
                    <count group_id="O2" value="483"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.8" lower_limit="52.90" upper_limit="60.96"/>
                    <measurement group_id="O2" value="57.9" lower_limit="51.04" upper_limit="65.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses to A/H1N1 vaccine strain measured in terms of Geometric Mean Titer ratios 28 days after the last vaccination</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criterion for the GMT ratio (adjusted analysis) was that the upper bound of the two-sided 95% confidence interval (CI) of the GMT ratio for the Comparator QIV GMT, divided by the Seqirus QIV GMT, should not exceed 1.5</non_inferiority_desc>
            <param_type>Geometric Mean Titer Ratio</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses to A/H3N2 vaccine strain measured in terms of Geometric Mean Titer ratios 28 days after the last vaccination</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criterion for the GMT ratio (adjusted analysis) was that the upper bound of the two-sided 95% CI of the GMT ratio for the Comparator QIV GMT, divided by the Seqirus QIV GMT, should not exceed 1.5</non_inferiority_desc>
            <param_type>Geometric Mean Titer Ratio</param_type>
            <param_value>1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.15</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses to B/YAM vaccine strain measured in terms of Geometric Mean Titer ratios 28 days after the last vaccination</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criterion for the GMT ratio (adjusted analysis) was that the upper bound of the two-sided 95% CI of the GMT ratio for the Comparator QIV GMT, divided by the Seqirus QIV GMT, should not exceed 1.5</non_inferiority_desc>
            <param_type>Geometric Mean Titer Ratio</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses to B/VIC vaccine strain measured in terms of Geometric Mean Titer ratios 28 days after the last vaccination</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criterion for the GMT ratio (adjusted analysis) was that the upper bound of the two-sided 95% CI of the GMT ratio for the Comparator QIV GMT, divided by the Seqirus QIV GMT, should not exceed 1.5</non_inferiority_desc>
            <param_type>Geometric Mean Titer Ratio</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Difference in Seroconversion Rate (SCR) for Each Virus Strain.</title>
        <description>Noninferiority of Seqirus QIV compared to comparator QIV will be assessed by seroconversion rate (SCR) for each viral strain. SCR is defined as the percentage of subjects with either a prevaccination HI titer &lt; 1:10 and a postvaccination HI titer ≥ 1:40, or a prevaccination HI titer ≥ 1:10 and a ≥ 4-fold increase in postvaccination HI titer. For the SCR comparison, the difference between the SCR for each vaccine (for each strain) will be determined.</description>
        <time_frame>Postvaccination (28 days after last vaccination)</time_frame>
        <population>The Per-Protocol Population comprised all subjects in the Evaluable Population who did not have any protocol deviations that were medically assessed as potentially impacting on immunogenicity results.</population>
        <group_list>
          <group group_id="O1">
            <title>Seqirus QIV</title>
            <description>Subjects 6 months through 59 months of age who received Seqirus Quadrivalent Inactivated Influenza Vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Comparator QIV</title>
            <description>Subjects 6 months through 59 months of age who received Comparator Quadrivalent Inactivated Influenza Vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>The Difference in Seroconversion Rate (SCR) for Each Virus Strain.</title>
          <description>Noninferiority of Seqirus QIV compared to comparator QIV will be assessed by seroconversion rate (SCR) for each viral strain. SCR is defined as the percentage of subjects with either a prevaccination HI titer &lt; 1:10 and a postvaccination HI titer ≥ 1:40, or a prevaccination HI titer ≥ 1:10 and a ≥ 4-fold increase in postvaccination HI titer. For the SCR comparison, the difference between the SCR for each vaccine (for each strain) will be determined.</description>
          <population>The Per-Protocol Population comprised all subjects in the Evaluable Population who did not have any protocol deviations that were medically assessed as potentially impacting on immunogenicity results.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1456"/>
                <count group_id="O2" value="484"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1456"/>
                    <count group_id="O2" value="484"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.1" lower_limit="76.9" upper_limit="81.1"/>
                    <measurement group_id="O2" value="68.8" lower_limit="64.5" upper_limit="72.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1455"/>
                    <count group_id="O2" value="484"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.3" lower_limit="80.2" upper_limit="84.2"/>
                    <measurement group_id="O2" value="84.9" lower_limit="81.4" upper_limit="88.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/YAM</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1456"/>
                    <count group_id="O2" value="484"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9" lower_limit="36.4" upper_limit="41.4"/>
                    <measurement group_id="O2" value="41.9" lower_limit="37.5" upper_limit="46.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/VIC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1456"/>
                    <count group_id="O2" value="483"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.2" lower_limit="57.6" upper_limit="62.7"/>
                    <measurement group_id="O2" value="61.1" lower_limit="56.6" upper_limit="65.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses to A/H1N1 vaccine strain measured in terms of Seroconversion Rate Difference 28 days after the last vaccination</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The noninferiority criterion for the SCR difference was that the upper bound of the two-sided 95% CI on the difference between SCRs for Comparator QIV minus the Seqirus QIV SCR should not exceed 10%.</non_inferiority_desc>
            <param_type>Seroconversion Rate Difference</param_type>
            <param_value>-10.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.4</ci_lower_limit>
            <ci_upper_limit>-5.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses to A/H3N2 vaccine strain measured in terms of Seroconversion Rate Difference 28 days after the last vaccination</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The noninferiority criterion for the SCR difference was that the upper bound of the two-sided 95% CI on the difference between SCRs for Comparator QIV minus the Seqirus QIV SCR should not exceed 10%.</non_inferiority_desc>
            <param_type>Seroconversion Rate Difference</param_type>
            <param_value>2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.54</ci_lower_limit>
            <ci_upper_limit>7.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses to B/YAM vaccine strain measured in terms of Seroconversion Rate Difference 28 days after the last vaccination</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The noninferiority criterion for the SCR difference was that the upper bound of the two-sided 95% CI on the difference between SCRs for Comparator QIV minus the Seqirus QIV SCR should not exceed 10%.</non_inferiority_desc>
            <param_type>Seroconversion Rate Difference</param_type>
            <param_value>3.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>8.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses to B/VIC vaccine strain measured in terms of Seroconversion Rate Difference 28 days after the last vaccination</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The noninferiority criterion for the SCR difference was that the upper bound of the two-sided 95% CI on the difference between SCRs for Comparator QIV minus the Seqirus QIV SCR should not exceed 10%.</non_inferiority_desc>
            <param_type>Seroconversion Rate Difference</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.2</ci_lower_limit>
            <ci_upper_limit>6.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Solicited Local Adverse Reactions and Solicited Systemic Adverse Events (AE)</title>
        <description>Frequency and severity of solicited local adverse reactions and systemic AEs for 7 days after each vaccination dose</description>
        <time_frame>Postvaccination (up to 7 days after vaccination)</time_frame>
        <population>The Solicited Safety Population comprises all subjects in the Full Analysis Set (FAS) who received at least one dose or partial dose of Study Vaccine and had provided any evaluable data on solicited events.</population>
        <group_list>
          <group group_id="O1">
            <title>Seqirus QIV</title>
            <description>Subjects 6 months through 59 months of age who received Seqirus Quadrivalent Inactivated Influenza Vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Comparator QIV</title>
            <description>Subjects 6 months through 59 months of age who received Comparator Quadrivalent Inactivated Influenza Vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Local Adverse Reactions and Solicited Systemic Adverse Events (AE)</title>
          <description>Frequency and severity of solicited local adverse reactions and systemic AEs for 7 days after each vaccination dose</description>
          <population>The Solicited Safety Population comprises all subjects in the Full Analysis Set (FAS) who received at least one dose or partial dose of Study Vaccine and had provided any evaluable data on solicited events.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1618"/>
                <count group_id="O2" value="545"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Solicited AEs, Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="940"/>
                    <measurement group_id="O2" value="312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solicited AEs, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="592"/>
                    <measurement group_id="O2" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solicited AEs, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solicited AEs, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solicited AEs, Local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="645"/>
                    <measurement group_id="O2" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solicited AEs, Systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="633"/>
                    <measurement group_id="O2" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cellulitis-like Reactions</title>
        <description>Frequency of cellulitis-like reactions for at least 28 days after each vaccination dose</description>
        <time_frame>Postvaccination (up to 28 days after each vaccination)</time_frame>
        <population>The Solicited Safety Population comprises all subjects in the FAS who received at least one dose or partial dose of Study Vaccine and had provided any evaluable data on solicited events.</population>
        <group_list>
          <group group_id="O1">
            <title>Seqirus QIV</title>
            <description>Subjects 6 months through 59 months of age who received Seqirus Quadrivalent Inactivated Influenza Vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Comparator QIV</title>
            <description>Subjects 6 months through 59 months of age who received Comparator Quadrivalent Inactivated Influenza Vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cellulitis-like Reactions</title>
          <description>Frequency of cellulitis-like reactions for at least 28 days after each vaccination dose</description>
          <population>The Solicited Safety Population comprises all subjects in the FAS who received at least one dose or partial dose of Study Vaccine and had provided any evaluable data on solicited events.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1618"/>
                <count group_id="O2" value="545"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Unsolicited AEs</title>
        <description>Frequency and severity of unsolicited AEs for at least 28 days after each vaccination dose</description>
        <time_frame>Postvaccination (up to 28 days after vaccination)</time_frame>
        <population>The Overall Safety Population was used for the analysis of overall and unsolicited adverse event safety and comprised all subjects in the FAS who received at least one dose or partial dose of Study Vaccine and have provided any evaluable follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Seqirus QIV</title>
            <description>Subjects 6 months through 59 months of age who received Seqirus Quadrivalent Inactivated Influenza Vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Comparator QIV</title>
            <description>Subjects 6 months through 59 months of age who received Comparator Quadrivalent Inactivated Influenza Vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Unsolicited AEs</title>
          <description>Frequency and severity of unsolicited AEs for at least 28 days after each vaccination dose</description>
          <population>The Overall Safety Population was used for the analysis of overall and unsolicited adverse event safety and comprised all subjects in the FAS who received at least one dose or partial dose of Study Vaccine and have provided any evaluable follow-up safety data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1673"/>
                <count group_id="O2" value="559"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unsolicited AEs, Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="536"/>
                    <measurement group_id="O2" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unsolicited AEs, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="285"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unsolicited AEs, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unsolicited AEs, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events (SAE)</title>
        <description>Frequency of SAEs for 180 days after the last vaccination dose. SAE = serious adverse events, AESI = adverse event of special interest</description>
        <time_frame>180 days after the last vaccination dose.</time_frame>
        <population>The Overall Safety Population was used for the analysis of overall and unsolicited adverse event safety and comprised all subjects in the FAS who received at least one dose or partial dose of Study Vaccine and have provided any evaluable follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Seqirus QIV</title>
            <description>Subjects 6 months through 59 months of age who received Seqirus Quadrivalent Inactivated Influenza Vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Comparator QIV</title>
            <description>Subjects 6 months through 59 months of age who received Comparator Quadrivalent Inactivated Influenza Vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (SAE)</title>
          <description>Frequency of SAEs for 180 days after the last vaccination dose. SAE = serious adverse events, AESI = adverse event of special interest</description>
          <population>The Overall Safety Population was used for the analysis of overall and unsolicited adverse event safety and comprised all subjects in the FAS who received at least one dose or partial dose of Study Vaccine and have provided any evaluable follow-up safety data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1673"/>
                <count group_id="O2" value="559"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAEs (Day 1 to Day 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs (Day 29 to Final Database Lock)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AESIs (Day 1 to Day 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AESIs (Day 29 to Final Database Lock)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean of Hemagglutination Titers (HI GMTs) Prevaccination (Day 1) and Postvaccination (Study Exit Visit) of Each Virus Strain</title>
        <description>The humoral immune response will be assessed for Seqirus QIV &amp; comparator QIV. Serum HI titers against the 4 influenza vaccine strains will be used to calculate geometric mean of HI titers prevaccination &amp; postvaccination.</description>
        <time_frame>28 days after last vaccination.</time_frame>
        <population>The Per-Protocol Population comprised all subjects in the Evaluable Population who did not have any protocol deviations that were medically assessed as potentially impacting on immunogenicity results.</population>
        <group_list>
          <group group_id="O1">
            <title>Seqirus QIV Cohort A</title>
            <description>Subjects 6 months through 35 months of age who received Seqirus Quadrivalent Inactivated Influenza Vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Seqirus QIV Cohort B</title>
            <description>Subjects 36 months through 59 months of age who received Seqirus Quadrivalent Inactivated Influenza Vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Comparator QIV Cohort A</title>
            <description>Subjects 6 months through 35 months of age who received Comparator Quadrivalent Inactivated Influenza Vaccine.</description>
          </group>
          <group group_id="O4">
            <title>Comparator QIV Cohort B</title>
            <description>Subjects 36 months through 59 months of age who received Comparator Quadrivalent Inactivated Influenza Vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Hemagglutination Titers (HI GMTs) Prevaccination (Day 1) and Postvaccination (Study Exit Visit) of Each Virus Strain</title>
          <description>The humoral immune response will be assessed for Seqirus QIV &amp; comparator QIV. Serum HI titers against the 4 influenza vaccine strains will be used to calculate geometric mean of HI titers prevaccination &amp; postvaccination.</description>
          <population>The Per-Protocol Population comprised all subjects in the Evaluable Population who did not have any protocol deviations that were medically assessed as potentially impacting on immunogenicity results.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="586"/>
                <count group_id="O2" value="870"/>
                <count group_id="O3" value="193"/>
                <count group_id="O4" value="291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1, Prevaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="586"/>
                    <count group_id="O2" value="870"/>
                    <count group_id="O3" value="193"/>
                    <count group_id="O4" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" lower_limit="12.30" upper_limit="15.57"/>
                    <measurement group_id="O2" value="60.7" lower_limit="53.97" upper_limit="68.20"/>
                    <measurement group_id="O3" value="14.9" lower_limit="12.25" upper_limit="18.22"/>
                    <measurement group_id="O4" value="68.7" lower_limit="55.84" upper_limit="84.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1, Postvaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="586"/>
                    <count group_id="O2" value="870"/>
                    <count group_id="O3" value="193"/>
                    <count group_id="O4" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184.9" lower_limit="165.15" upper_limit="207.05"/>
                    <measurement group_id="O2" value="590.2" lower_limit="548.62" upper_limit="634.93"/>
                    <measurement group_id="O3" value="168.3" lower_limit="137.69" upper_limit="205.62"/>
                    <measurement group_id="O4" value="469.2" lower_limit="413.72" upper_limit="532.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, Prevaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="586"/>
                    <count group_id="O2" value="870"/>
                    <count group_id="O3" value="193"/>
                    <count group_id="O4" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="12.48" upper_limit="16.39"/>
                    <measurement group_id="O2" value="62.4" lower_limit="55.50" upper_limit="70.19"/>
                    <measurement group_id="O3" value="16.4" lower_limit="12.86" upper_limit="20.91"/>
                    <measurement group_id="O4" value="65.5" lower_limit="53.76" upper_limit="79.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, Postvaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="585"/>
                    <count group_id="O2" value="870"/>
                    <count group_id="O3" value="193"/>
                    <count group_id="O4" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184.9" lower_limit="164.57" upper_limit="207.65"/>
                    <measurement group_id="O2" value="778.6" lower_limit="710.83" upper_limit="852.82"/>
                    <measurement group_id="O3" value="247.5" lower_limit="202.14" upper_limit="302.95"/>
                    <measurement group_id="O4" value="1047" lower_limit="911.69" upper_limit="1202.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/YAM, Prevaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="586"/>
                    <count group_id="O2" value="870"/>
                    <count group_id="O3" value="193"/>
                    <count group_id="O4" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="5.66" upper_limit="6.13"/>
                    <measurement group_id="O2" value="7.9" lower_limit="7.55" upper_limit="8.33"/>
                    <measurement group_id="O3" value="5.8" lower_limit="5.47" upper_limit="6.22"/>
                    <measurement group_id="O4" value="8.3" lower_limit="7.58" upper_limit="9.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/YAM, Postvaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="586"/>
                    <count group_id="O2" value="870"/>
                    <count group_id="O3" value="193"/>
                    <count group_id="O4" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" lower_limit="14.33" upper_limit="17.00"/>
                    <measurement group_id="O2" value="35.4" lower_limit="32.73" upper_limit="38.26"/>
                    <measurement group_id="O3" value="16.3" lower_limit="14.03" upper_limit="18.95"/>
                    <measurement group_id="O4" value="44.1" lower_limit="38.30" upper_limit="50.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/VIC, Prevaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="586"/>
                    <count group_id="O2" value="870"/>
                    <count group_id="O3" value="193"/>
                    <count group_id="O4" value="290"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="6.75" upper_limit="7.55"/>
                    <measurement group_id="O2" value="9.6" lower_limit="9.04" upper_limit="10.19"/>
                    <measurement group_id="O3" value="6.9" lower_limit="6.26" upper_limit="7.53"/>
                    <measurement group_id="O4" value="10.4" lower_limit="9.35" upper_limit="11.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/VIC, Postvaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="586"/>
                    <count group_id="O2" value="870"/>
                    <count group_id="O3" value="193"/>
                    <count group_id="O4" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8" lower_limit="36.02" upper_limit="44.04"/>
                    <measurement group_id="O2" value="72.1" lower_limit="65.62" upper_limit="79.25"/>
                    <measurement group_id="O3" value="31.9" lower_limit="26.88" upper_limit="37.81"/>
                    <measurement group_id="O4" value="85.9" lower_limit="73.16" upper_limit="100.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Rates (SCRs) of Each Virus Strain</title>
        <description>The humoral immune response will be assessed for Seqirus QIV &amp; comparator QIV. Serum HI titers against the 4 influenza vaccine strains will be used to calculate SCRs defined as the % of subjects with either a prevaccination HI titer &lt; 1:10 and a postvaccination HI titer ≥ 1:40 or a prevaccination titer ≥ 1:10 and a ≥ 4-fold increase in postvaccination titer.</description>
        <time_frame>28 days after last vaccination</time_frame>
        <population>The Per-Protocol Population comprised all subjects in the Evaluable Population who did not have any protocol deviations that were medically assessed as potentially impacting on immunogenicity results.</population>
        <group_list>
          <group group_id="O1">
            <title>Seqirus QIV Cohort A</title>
            <description>Subjects 6 months through 35 months of age who received Seqirus Quadrivalent Inactivated Influenza Vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Seqirus QIV Cohort B</title>
            <description>Subjects 36 months through 59 months of age who received Seqirus Quadrivalent Inactivated Influenza Vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Comparator QIV Cohort A</title>
            <description>Subjects 6 months through 35 months of age who received Comparator Quadrivalent Inactivated Influenza Vaccine.</description>
          </group>
          <group group_id="O4">
            <title>Comparator QIV Cohort B</title>
            <description>Subjects 36 months through 59 months of age who received Comparator Quadrivalent Inactivated Influenza Vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Rates (SCRs) of Each Virus Strain</title>
          <description>The humoral immune response will be assessed for Seqirus QIV &amp; comparator QIV. Serum HI titers against the 4 influenza vaccine strains will be used to calculate SCRs defined as the % of subjects with either a prevaccination HI titer &lt; 1:10 and a postvaccination HI titer ≥ 1:40 or a prevaccination titer ≥ 1:10 and a ≥ 4-fold increase in postvaccination titer.</description>
          <population>The Per-Protocol Population comprised all subjects in the Evaluable Population who did not have any protocol deviations that were medically assessed as potentially impacting on immunogenicity results.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="586"/>
                <count group_id="O2" value="870"/>
                <count group_id="O3" value="193"/>
                <count group_id="O4" value="291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="586"/>
                    <count group_id="O2" value="870"/>
                    <count group_id="O3" value="193"/>
                    <count group_id="O4" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.9" lower_limit="78.6" upper_limit="84.9"/>
                    <measurement group_id="O2" value="77.1" lower_limit="74.2" upper_limit="79.9"/>
                    <measurement group_id="O3" value="80.3" lower_limit="74.0" upper_limit="85.7"/>
                    <measurement group_id="O4" value="61.2" lower_limit="55.3" upper_limit="66.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="585"/>
                    <count group_id="O2" value="870"/>
                    <count group_id="O3" value="193"/>
                    <count group_id="O4" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.4" lower_limit="79.1" upper_limit="85.4"/>
                    <measurement group_id="O2" value="82.2" lower_limit="79.5" upper_limit="84.7"/>
                    <measurement group_id="O3" value="85.0" lower_limit="79.1" upper_limit="89.7"/>
                    <measurement group_id="O4" value="84.9" lower_limit="80.2" upper_limit="88.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/YAM</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="586"/>
                    <count group_id="O2" value="870"/>
                    <count group_id="O3" value="193"/>
                    <count group_id="O4" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" lower_limit="19.2" upper_limit="26.1"/>
                    <measurement group_id="O2" value="49.9" lower_limit="46.5" upper_limit="53.3"/>
                    <measurement group_id="O3" value="26.9" lower_limit="20.8" upper_limit="33.8"/>
                    <measurement group_id="O4" value="51.9" lower_limit="46.0" upper_limit="57.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/VIC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="586"/>
                    <count group_id="O2" value="870"/>
                    <count group_id="O3" value="193"/>
                    <count group_id="O4" value="290"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.9" lower_limit="48.8" upper_limit="57.0"/>
                    <measurement group_id="O2" value="65.1" lower_limit="61.8" upper_limit="68.2"/>
                    <measurement group_id="O3" value="49.7" lower_limit="42.5" upper_limit="57.0"/>
                    <measurement group_id="O4" value="68.6" lower_limit="62.9" upper_limit="73.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroprotection Rates of Each Virus Strain</title>
        <description>The humoral immune response will be assessed for Seqirus QIV &amp; comparator QIV. Serum HI titers against the 4 influenza vaccine strains will be used to calculate the percentage of subjects with a titer ≥40 (seroprotection rates) at Day 1 and at Study Exit Visit.</description>
        <time_frame>28 days after last vaccination.</time_frame>
        <population>The Per-Protocol Population comprised all subjects in the Evaluable Population who did not have any protocol deviations that were medically assessed as potentially impacting on immunogenicity results.</population>
        <group_list>
          <group group_id="O1">
            <title>Seqirus QIV Cohort A</title>
            <description>Subjects 6 months through 35 months of age who received Seqirus Quadrivalent Inactivated Influenza Vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Seqirus QIV Cohort B</title>
            <description>Subjects 36 months through 59 months of age who received Seqirus Quadrivalent Inactivated Influenza Vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Comparator QIV Cohort A</title>
            <description>Subjects 6 months through 35 months of age who received Comparator Quadrivalent Inactivated Influenza Vaccine.</description>
          </group>
          <group group_id="O4">
            <title>Comparator QIV Cohort B</title>
            <description>Subjects 36 months through 59 months of age who received Comparator Quadrivalent Inactivated Influenza Vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Rates of Each Virus Strain</title>
          <description>The humoral immune response will be assessed for Seqirus QIV &amp; comparator QIV. Serum HI titers against the 4 influenza vaccine strains will be used to calculate the percentage of subjects with a titer ≥40 (seroprotection rates) at Day 1 and at Study Exit Visit.</description>
          <population>The Per-Protocol Population comprised all subjects in the Evaluable Population who did not have any protocol deviations that were medically assessed as potentially impacting on immunogenicity results.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="586"/>
                <count group_id="O2" value="870"/>
                <count group_id="O3" value="193"/>
                <count group_id="O4" value="291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="586"/>
                    <count group_id="O2" value="870"/>
                    <count group_id="O3" value="193"/>
                    <count group_id="O4" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.1" lower_limit="87.4" upper_limit="92.4"/>
                    <measurement group_id="O2" value="99.1" lower_limit="98.2" upper_limit="99.6"/>
                    <measurement group_id="O3" value="88.6" lower_limit="83.3" upper_limit="92.7"/>
                    <measurement group_id="O4" value="98.3" lower_limit="96.0" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="585"/>
                    <count group_id="O2" value="870"/>
                    <count group_id="O3" value="193"/>
                    <count group_id="O4" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5" lower_limit="90.0" upper_limit="94.5"/>
                    <measurement group_id="O2" value="98.4" lower_limit="97.3" upper_limit="99.1"/>
                    <measurement group_id="O3" value="95.3" lower_limit="91.3" upper_limit="97.8"/>
                    <measurement group_id="O4" value="98.6" lower_limit="96.5" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/YAM</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="586"/>
                    <count group_id="O2" value="870"/>
                    <count group_id="O3" value="193"/>
                    <count group_id="O4" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7" lower_limit="21.3" upper_limit="28.4"/>
                    <measurement group_id="O2" value="57.1" lower_limit="53.8" upper_limit="60.4"/>
                    <measurement group_id="O3" value="29.0" lower_limit="22.7" upper_limit="36.0"/>
                    <measurement group_id="O4" value="61.5" lower_limit="55.7" upper_limit="67.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/VIC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="586"/>
                    <count group_id="O2" value="870"/>
                    <count group_id="O3" value="193"/>
                    <count group_id="O4" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6" lower_limit="51.5" upper_limit="59.7"/>
                    <measurement group_id="O2" value="71.0" lower_limit="67.9" upper_limit="74.0"/>
                    <measurement group_id="O3" value="52.8" lower_limit="45.6" upper_limit="60.1"/>
                    <measurement group_id="O4" value="75.3" lower_limit="69.9" upper_limit="80.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Increase (GMFI) of Each Virus Strain</title>
        <description>The humoral immune response will be assessed for Seqirus QIV &amp; comparator QIV. Serum HI titers against the 4 influenza vaccine strains will be used to calculate GMFIs, defined as the geometric mean fold titer change (rise) from Day 1 to Study Exit Visit.</description>
        <time_frame>Prevaccination (Day 1) and Postvaccination (28 days after last vaccination)</time_frame>
        <population>The Per-Protocol Population comprised all subjects in the Evaluable Population who did not have any protocol deviations that were medically assessed as potentially impacting on immunogenicity results.</population>
        <group_list>
          <group group_id="O1">
            <title>Seqirus QIV Cohort A</title>
            <description>Subjects 6 months through 35 months of age who received Seqirus Quadrivalent Inactivated Influenza Vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Seqirus QIV Cohort B</title>
            <description>Subjects 36 months through 59 months of age who received Seqirus Quadrivalent Inactivated Influenza Vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Comparator QIV Cohort A</title>
            <description>Subjects 6 months through 35 months of age who received Comparator Quadrivalent Inactivated Influenza Vaccine.</description>
          </group>
          <group group_id="O4">
            <title>Comparator QIV Cohort B</title>
            <description>Subjects 36 months through 59 months of age who received Comparator Quadrivalent Inactivated Influenza Vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Increase (GMFI) of Each Virus Strain</title>
          <description>The humoral immune response will be assessed for Seqirus QIV &amp; comparator QIV. Serum HI titers against the 4 influenza vaccine strains will be used to calculate GMFIs, defined as the geometric mean fold titer change (rise) from Day 1 to Study Exit Visit.</description>
          <population>The Per-Protocol Population comprised all subjects in the Evaluable Population who did not have any protocol deviations that were medically assessed as potentially impacting on immunogenicity results.</population>
          <units>Fold Change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="586"/>
                <count group_id="O2" value="870"/>
                <count group_id="O3" value="193"/>
                <count group_id="O4" value="291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="586"/>
                    <count group_id="O2" value="870"/>
                    <count group_id="O3" value="193"/>
                    <count group_id="O4" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" lower_limit="11.98" upper_limit="14.90"/>
                    <measurement group_id="O2" value="9.7" lower_limit="8.90" upper_limit="10.64"/>
                    <measurement group_id="O3" value="11.3" lower_limit="9.40" upper_limit="13.49"/>
                    <measurement group_id="O4" value="6.8" lower_limit="5.83" upper_limit="7.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="585"/>
                    <count group_id="O2" value="870"/>
                    <count group_id="O3" value="193"/>
                    <count group_id="O4" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="11.62" upper_limit="14.50"/>
                    <measurement group_id="O2" value="12.5" lower_limit="11.42" upper_limit="13.62"/>
                    <measurement group_id="O3" value="15.1" lower_limit="12.60" upper_limit="18.08"/>
                    <measurement group_id="O4" value="16.0" lower_limit="13.62" upper_limit="18.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/YAM</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="586"/>
                    <count group_id="O2" value="870"/>
                    <count group_id="O3" value="193"/>
                    <count group_id="O4" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="2.45" upper_limit="2.86"/>
                    <measurement group_id="O2" value="4.5" lower_limit="4.17" upper_limit="4.77"/>
                    <measurement group_id="O3" value="2.8" lower_limit="2.45" upper_limit="3.19"/>
                    <measurement group_id="O4" value="5.3" lower_limit="4.67" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/VIC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="586"/>
                    <count group_id="O2" value="870"/>
                    <count group_id="O3" value="193"/>
                    <count group_id="O4" value="290"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="5.11" upper_limit="6.09"/>
                    <measurement group_id="O2" value="7.5" lower_limit="6.93" upper_limit="8.15"/>
                    <measurement group_id="O3" value="4.6" lower_limit="3.97" upper_limit="5.42"/>
                    <measurement group_id="O4" value="8.2" lower_limit="7.18" upper_limit="9.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Non-serious unsolicited AEs and serious AEs were collected from Day 1 through Day 180</time_frame>
      <desc>Of the 2247 subjects who provided consent, 7 subjects discontinued from the study and did not receive any vaccination; and 8 subjects had no reported safety data. Therefore, 2232 subjects were included in the overall safety population.
Seqirus QIV N = 1673 Comparator QIV N = 559</desc>
      <group_list>
        <group group_id="E1">
          <title>Seqirus QIV</title>
          <description>Subjects 6 months through 59 months of age who received Seqirus Quadrivalent Inactivated Influenza Vaccine.</description>
        </group>
        <group group_id="E2">
          <title>Comparator QIV</title>
          <description>Subjects 6 months through 59 months of age who received Comparator Quadrivalent Inactivated Influenza Vaccine.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1673"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="559"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1673"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="559"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1673"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="559"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Croup Infectious</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1673"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="559"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1673"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="559"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1673"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="559"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1673"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="559"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1673"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="559"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1673"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="559"/>
              </event>
              <event>
                <sub_title>Foreign body aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1673"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="559"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1673"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="559"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1673"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="559"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1673"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="559"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1673"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="559"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="320" subjects_at_risk="1673"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="559"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="100" subjects_affected="91" subjects_at_risk="1673"/>
                <counts group_id="E2" events="29" subjects_affected="25" subjects_at_risk="559"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="72" subjects_affected="67" subjects_at_risk="1673"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="559"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="167" subjects_affected="153" subjects_at_risk="1673"/>
                <counts group_id="E2" events="52" subjects_affected="41" subjects_at_risk="559"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="155" subjects_affected="134" subjects_at_risk="1673"/>
                <counts group_id="E2" events="63" subjects_affected="53" subjects_at_risk="559"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Seqirus agreements and restrictions on publishing may vary with individual investigators; however, Seqirus will not prohibit any investigator from publishing. Seqirus supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Study Disclosure Manager</name_or_title>
      <organization>Seqirus</organization>
      <phone>1-855-358-8966</phone>
      <email>Seqirus.ClinicalTrials@Seqirus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

